Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Dedicated

- PMLiVE

N4 Pharma appoints David Solomon as CEO

The company is to be renamed Thalia Therapeutics to reflect its strategic transition

- PMLiVE

Why stigma is a launch risk in rare disease – and what commercial leaders can do about it

Rare disease launches are complex by nature. Yet one of the most consistent risks we see is rarely treated as a launch issue at all: stigma.

Havas Life London

- PMLiVE

New report identifies stigma as a structural barrier in rare disease

The study finds that healthcare settings are a leading source of stigma for people living with rare conditions

- PMLiVE

Patient-centricity in rare disease: accelerating the path to treatment

By Chris Moore

- PMLiVE

GenAI in healthcare: why privacy and literacy matter more than the tech

By Dimitri Challouma

Involvement of children and young people in research and publication development

From ‘why’ to ‘how’: patient partnership across age groups in research and publications

By Sarah Mohamad

Amiculum

- PMLiVE

From Static to Strategic: The 2026 Playbook for Longitudinal Pharma Interaction

Stop pushing content at a burnt-out audience and start creating "Digital Magnetism." Join Impetus Digital to unlock the 2026 Engagement Toolkit—a deep dive into the immersive, longitudinal strategies and newly...

Impetus Digital

- PMLiVE

Novo Nordisk and Vivtex partner in deal worth up to $2.1bn

The companies aim to develop next-generation oral medicines for obesity and diabetes

- PMLiVE

AI-enabled, human-interpreted: the future of pharma marketing insights is precision intelligence

By Abigail Stuart

- PMLiVE

It’s time for an end to pharma exceptionalism

By Mark Ralphs

- PMLiVE

Data, Evidence, Education: Tackling the Global Multi‑Trillion‑Dollar Rare Disease Burden

Rare diseases are individually uncommon, yet together they affect an estimated 300 million+ people worldwide and touch the lives of over one billion when families and caregivers are included. For...

Medscape Education

- PMLiVE

GSK to acquire 35Pharma for $950m including a potential drug for pulmonary hypertension

PH has a five‑year survival rate of only around 50% and affects up to 82 million people worldwide

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links